Saturday 17 October 2026
Export BGM’s income statement to Excel — free account
BGM Group Ltd.
BGM Healthcare Drug Manufacturers Specialty & Generic
BGM Group Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $37.9 million, up 51.1% from fiscal 2024.
8.65
0.06
+0.70%
Follow BGM
| Mar '26 | Sep '25 | Mar '25 | Sep '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.43 | 0.36 | 0.85 | 2.24 | |
Current Ratio |
1.25 | 1.24 | 1.82 | 3.39 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.25% | 0.00% | 0.77% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.69) | (1.41) | (2.30) | (2.31) | |
Intangible Assets out of Total Assets |
0.84 | 0.82 | 0.67 | 0.09 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | — | 0.00 | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
1.83 | (4.44) | (4.07) | (2.31) | |
Working Capital |
9.15 | 9.95 | 19.36 | 20.99 | |
Capital Expenditures |
(0.66) | (2.07) | (1.02) | (2.85) | |
Net Current Asset Value |
8.94 | 9.63 | 19.04 | 20.86 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.45 | 3.12 | 3.55 | 1.18 | |
Average Payables |
4.51 | 5.07 | 6.41 | 5.06 | |
Average Inventory |
11.80 | 12.55 | 9.87 | 6.96 | |
Average Assets |
243.20 | 242.54 | 135.81 | 58.77 | |
Average Common Equity |
222.34 | 218.12 | 119.11 | 49.53 |
Columns are period end dates